Aetion Rapid Start: AML

Answer research questions never before possible with a novel longitudinal real-world dataset in AML

With new therapies coming to market to treat underserved populations with acute myelogenous leukemia (AML), real-world evidence (RWE) is critical to increase the totality of evidence for regulatory submissions and to inform commercial and payer strategy. Yet, finding real-world data (RWD) that is fit to answer your research question can be challenging.


Aetion® Rapid Start: AML is designed to meet that challenge by providing access to a fully longitudinal, built-for-purpose AML dataset on our leading regulatory-grade RWE platform, Aetion® Substantiate, with AML data already optimized and ready to analyze. Request a demo to learn how Substantiate and the Aetion team can help you answer research questions never before possible, enabling higher quality decisions to move the needle in patient care.

“As new therapies are being developed to treat historically underserved patient segments within AML, life sciences companies will need deep, structured real-world data that captures a patient’s journey across a number of care settings. We are thrilled to partner with xCures to provide and evolve a patient-centric solution to meet this need.”


- Wendy Turenne

SVP Real-World Data and Delivery Operations, Aetion

Aetion is changing the way real-world evidence is generated in AML

Built-for-purpose AML dataset

Aetion partnered with xCures to develop a novel dataset that is built for AML evidence generation based on our SPIFD framework. The xCures dataset:

Oncology expertise

Scientific, data, and regulatory oncology expertise throughout an engagement to ensure best practices from initial analysis of data to study design and execution. 


A backdrop of oncology expertise from a team responsible for authoring 115+ peer-reviewed publications, 85+ years of oncology experience across oncology experts, and a network of standard-setting collaborations including the FDA’s Oncology Center of Excellence and CARE Oncology.

Leading regulatory-grade RWE generation

Leading regulatory-grade RWE generation through a platform that enables custom lines of therapy analysis. Applications scientifically validated to analyze real-world data and produce transparent and rapid evidence on safety, effectiveness, and value. xCures’ AML data is already optimized in the platform and applications and is ready to analyze.